1. Selecting MM Therapy in Patients With Comorbidities

2. Agenda

3. Program Goals and Disclosure

4. Managing the Patient With Diabetes and MM

5. Diabetes and MM

6. Corticosteroids

7. Peripheral Neuropathy in Multiple Myeloma

8. Diabetic Autonomic Neuropathy

9. Managing Peripheral Neuropathy

10. Key Takeaways

11. MM Therapeutic Agents Associated AEs

12. Treating Patients With Renal Impairment

13. Renal Impairment in MM

14. Management

15. Dose Modifications With Renal Impairment

16. Key Takeaways

17. Treating Patients With a History of Thromboembolism

18. Risk of Thromboembolism in MM

19. VTE Incidence With Immunomodulatory Agents

21. Prophylaxis

22. Management

23. Treating Patients With a History of Cardiac Disease

24. Background

25. ASPIRE KRd vs Rd

26. ENDEAVOR Carfilzomib/Dex vs Bortezomib/Dex

27. Carfilzomib in Patients With Cardiac History

28. Other MM Agents and Cardiotoxicity

29. Balancing Efficacy and Convenience for the Frail Patient

30. MM Patients Are Heterogeneous

31. IMWG Geriatric Assessment

32. IMWG Frailty Score ADL and IADL Components

33. FIRST Trial Continuous Rd vs Rd-18 vs MPT

34. UPFRONT VD vs VTP vs VMP

35. Key Takeaways

36. Optimizing Adherence for Patients With Comorbidities

37. Components of Adherence

38. Patient and Caregiver Education

39. Impact of Comorbidities

40. Abbreviations

41. Abbreviations

42. Abbreviations